An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma
This study has been completed.
Massachusetts General Hospital
Dana-Farber Cancer Institute
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Ryan Sullivan, M.D., Massachusetts General Hospital
First received: March 1, 2010
Last updated: June 7, 2016
Last verified: January 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||June 2016|
|Primary Completion Date:||February 2013 (Final data collection date for primary outcome measure)|